Anti-interferon alpha antibodies and autoantibodies in patients with Beh double dagger et's disease uveitis treated with recombinant human interferon alpha-2a

Abstract

Recombinant human (rh) interferon alpha2a (IFN-alpha 2a) therapy is successfully used for the treatment of Beh double dagger et's disease (BD) uveitis refractory to conventional immunosuppressive treatment.